Showing results (1891-1900 of 2,001) with videos related to
Sort By:
Pageof 201
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancerM Catherine Pietanza, Shirish M Gadgeel, Afshin Dowlati, et al.Proceedings of the National Academy of Sciences of the United States of America|May 18, 2005
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibEunice L Kwak, Raffaella Sordella, Daphne W Bell, et al.Ecology|January 28, 2017
Circumpolar analysis of the Adélie Penguin reveals the importance of environmental variability in phenological mismatchCasey Youngflesh, Stephanie Jenouvrier, Yun Li, et al.Critical Care Medicine|March 7, 2018
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin IIJames A Tumlin, Raghavan Murugan, Adam M Deane, et al.American Journal of Human Genetics|April 29, 1998
Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlationB M Manning, K A Quane, H Ording, et al.World Journal of Surgery|August 13, 2010
Resident workload, pager communications, and quality of careShaun P Patel, Jay S Lee, David N Ranney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Novel agents in the treatment of lung cancer: Fourth Cambridge ConferenceThomas J Lynch, Philip D Bonomi, Charles Butts, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.Journal of Psychopharmacology (Oxford, England)|November 4, 2025
Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendationsJack E Henningfield, Sandra D Comer, Matthew L Banks, et al.Pageof 201